S
Sean L. Petersen
Researcher at University of Texas Southwestern Medical Center
Publications - 4
Citations - 1674
Sean L. Petersen is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: RNA interference & Caspase 8. The author has an hindex of 4, co-authored 4 publications receiving 1591 citations.
Papers
More filters
Journal ArticleDOI
Argonaute2 Cleaves the Anti-Guide Strand of siRNA during RISC Activation
TL;DR: It is shown that both strands of siRNA get loaded onto Ago2 protein in Drosophila S2 cell extracts and this cleavage event is important for the removal of the anti-guide strand from Ago2protein and activation of RISC.
Journal ArticleDOI
Autocrine TNFα Signaling Renders Human Cancer Cells Susceptible to Smac-Mimetic-Induced Apoptosis
Sean L. Petersen,Lai Wang,Asligul Yalcin-Chin,Lin Li,Michael Peyton,John D. Minna,Patrick G. Harran,Xiaodong Wang +7 more
TL;DR: A small molecule mimetic of Smac/Diablo that specifically counters the apoptosis-inhibiting activity of IAP proteins has been shown to enhance apoptosis induced by cell surface death receptors as well as chemotherapeutic drugs.
Journal ArticleDOI
Genome-Wide siRNA-Based Functional Genomics of Pigmentation Identifies Novel Genes and Pathways That Impact Melanogenesis in Human Cells
Anand K. Ganesan,Hsiang Ho,Brian O. Bodemann,Sean L. Petersen,Jayavani Aruri,Shiney Koshy,Zachary Richardson,Lu Q. Le,Tatiana B. Krasieva,Michael G. Roth,Patrick J. Farmer,Michael A. White +11 more
TL;DR: The power of RNAi-based functional genomics to identify novel genes, pathways, and pharmacologic agents that impact a biological phenotype and operate outside of preconceived mechanistic relationships is illustrated.
Journal ArticleDOI
Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression
TL;DR: This work reports here a means through which cancer cells mediate resistance to Smac mimetic/TNFα-induced apoptosis and corresponding strategies to overcome such resistance, and uses the PI3K inhibitor, LY294002, to overcome resistance to cIAP2 up-regulation.